Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | NOS1 | P29475 | 6/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31662833 | 1.00 | ALDH1A1 (0.48) | ALDH1A1PNMTENPP2TSHRLOXL2 | |
| Hydrochloric Acid SCHEMBL25180658 | 0.98 | ALDH1A1 (0.47) | ALDH1A1PNMTENPP2TSHRLOXL2 | |
| SCHEMBL31318817 | 0.83 | TAAR1 (0.57) | ALDH1A1TSHRLOXL2NOS1NOS2 | |
| SCHEMBL6827042 | 0.83 | TAAR1 (0.57) | ALDH1A1TSHRLOXL2NOS1NOS2 | |
| Tert-Butyl Formate SCHEMBL27816894 | 0.82 | AOC3 (0.39) | ALDH1A1PNMTENPP2TSHRLOXL2 | |
| SCHEMBL11861528 | 0.82 | HDAC1 (0.60) | ALDH1A1TSHRNOS1HDAC1HDAC6 | |
| SCHEMBL21649568 | 0.82 | PNMT (0.44) | ALDH1A1PNMTENPP2LOXL2NOS1 | |
| SCHEMBL2568377 | 0.80 | TAAR1 (0.55) | ALDH1A1TSHR | |
| SCHEMBL129446 | 0.80 | SIGMAR1 (0.51) | ALDH1A1TSHRHDAC1HDAC6KMT2A | |
| SCHEMBL30966769 | 0.80 | SIGMAR1 (0.51) | ALDH1A1TSHRHDAC1HDAC6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037412-B1 | INDOLE AMIDE COMPOUND AS INHIBITOR OF NECROSIS | LG CHEMICAL LTD (KR) | 2020-09-30 | — | — | EP | claimed |
| WO-2012154680-A2 | MODIFIED AND DERIVATIZED β-GLUCAN COMPOUNDS, COMPOSITIONS, AND METHODS | BIOTHERA, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| CN-114539223-B | Aryl-containing aza-seven-membered ring compound and preparation method and application thereof | 中国药科大学 | 2024-04-09 | — | — | CN | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3452477-B1 | ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B C I PHARMA (BE) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023078451-A1 | COMPOUND USED AS CDK7 KINASE INHIBITOR AND USE THEREOF | 浙江同源康医药股份有限公司 | 2023-05-11 | — | — | WO | disclosed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | disclosed |
| CN-114539223-A | Aryl-containing aza-heptacyclic compound and preparation method and application thereof | 中国药科大学 | 2022-05-27 | — | — | CN | disclosed |
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | B.C.I. PHARMA (BE) | 2022-02-01 | — | — | US | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| CN-1139383-A | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | WARNER LAMBERT CO (US) | 1997-01-01 | — | — | CN | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
| EP-0355098-A1 | NOVEL SULFONAMIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE NEW SULFONAMIDES | HUHTAMÄKI OY (FI) | 1990-02-28 | — | — | EP | disclosed |
| WO-1988007991-A1 | NOVEL SULFONAMIDES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE NEW SULFONAMIDES | Huhtamäki Oy (FI) | 1988-10-20 | — | — | WO | disclosed |
| US-4686285-A | DYEING POLYMERS, NATURAL FIBERS, LEATHER OR PAPER | SANDOZ LTD. (CH) | 1987-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236093-B2 | Adenine derivatives as protein kinase inhibitors | ADK, TNNI3K, TNK2 | ALDH1A1 3196/4885PNMT 1739/4885ENPP2 524/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | ALDH1A1 1943/4885PNMT 364/4885ENPP2 680/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | ALDH1A1 3190/4885PNMT 4446/4885ENPP2 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.